{
    "Trade/Device Name(s)": [
        "Immunalysis Carisoprodol Metabolite / Meprobamate Urine HEIA"
    ],
    "Submitter Information": "Immunalysis Corporation",
    "510(k) Number": "K190397",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN170010"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBK"
    ],
    "Summary Letter Date": "October 3, 2019",
    "Summary Letter Received Date": "October 4, 2019",
    "Submission Date": "November 13, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.3590"
    ],
    "Regulation Name(s)": [
        "Meprobamate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Meprobamate",
        "Carisoprodol"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzers",
        "Olympus AU400e analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Immunalysis Carisoprodol Metabolite / Meprobamate Urine HEIA qualitative enzyme immunoassay for meprobamate in urine using automated analyzers",
    "Indications for Use Summary": "Qualitative analysis of carisoprodol metabolite, meprobamate, at a cutoff of 280 ng/mL in human urine for use in laboratories with automated clinical chemistry analyzers; provides preliminary analytical results requiring confirmatory testing by GC-MS or LC-MS/MS",
    "fda_folder": "Toxicology"
}